Key result
A 42-year-old man developed neuroleptic malignant syndrome after receiving high-dose parenteral haloperidol, which resolved upon drug discontinuation and treatment with bromocriptine and lorazepam.
Why the study?
Does parenteral haloperidol cause Neuroleptic Malignant Syndrome in a schizophrenic patient?
Case Report (n=1)
Does parenteral haloperidol cause Neuroleptic Malignant Syndrome in a schizophrenic patient?
Parenteral haloperidol can induce Neuroleptic Malignant Syndrome, which can be successfully managed by prompt discontinuation of the offending agent and administration of bromocriptine and lorazepam.
Parenteral haloperidol may trigger NMS in schizophrenia; this Level 5 case leaves open causality and risk quantification.
A 42-year-old adult schizophrenic patient developed high fever (106 degree Fahrenheit), mental state changes and muscle rigidity after treatment with parenteral haloperidol. Neuroleptic malignant syndrome (NMS) associated with haloperidol was suspected. Other differentials were excluded. Haloperidol was discontinued and prompt treatment with bromocriptine and lorazepam was started resulting in a good recovery. Because of the temporal relationship between the patient's improvement with the discontinuation of haloperidol and treatment with lorazepam and bromocriptine, the diagnosis was believed to be haloperidol-induced NMS. TAJ 2019; 32(2): 62-63
No takes yet. Share an insight, caveat, or question.
Md Fajlul Kabir Bhuiyan (2020) conducted a case report in Schizophrenia (n=1). Haloperidol was evaluated on Development of Neuroleptic Malignant Syndrome. A 42-year-old man developed neuroleptic malignant syndrome after receiving high-dose parenteral haloperidol, which resolved upon drug discontinuation and treatment with bromocriptine and lorazepam.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: